Fewer than 10% of patients that would benefit from GLP-1 drugs such as Wegovy are able to get them, caution the World Health Organization as it publishes its initial guidance on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for more widespread and fairer availability to this class of drugs.
Per forecasts, more than two billion could be obese by 2030 without intervention.
"Our latest guidelines acknowledges that excess weight is a long-term condition that can be managed with holistic and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are significant obstacles to broad access to the jabs that can help people shift considerable body mass, says the organization.
Weight-Loss Drug Shortage
Even in the present best projected outlook, the supply of these medications could only cover about 100 million people – less than 10% of the global need, as stated by the WHO.
The advice urges governments and firms to expand access, via strategies like licensing agreements.
The intellectual property rights on semaglutide – the core ingredient of a leading brand – is due to expire in several nations in 2026.
The Way Weight-Loss Drugs Function
The injections mimick a biological compound to slow digestion, reduce hunger and enhance the sense of being full so people eat less.
Individuals usually see weight reduction within a few weeks of beginning the regular doses.
Evidence indicates patients may regain a significant portion a year later of discontinuing the drug, when their typical hunger come back.
To be carrying excess weight elevates your likelihood for developing medical conditions, such as type 2 diabetes, heart disease, brain attack, and specific cancers.
Excess weight affects individuals in all nations and was linked to 3.7 million deaths worldwide in 2024, per the WHO.
